Oxidized LDL and anti‐oxLDL antibody levels in peripheral atherosclerotic disease

References

• Toshima S., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2243–7
   PubMed Web of Science ®Google Scholar
• Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Modifications of low‐density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Inoue T., Uchida T., Kamishirado H., Takayanagi K., Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardio 2001; 37: 1871–6
   PubMed Web of Science ®Google Scholar
• Fang J. C., Kinlay S., Behrendt D., Hikita H., Witztum J. L., Selwyn A. P., et al. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol 2002; 22: 2044–8
   PubMedGoogle Scholar
• Erkkilä A. T., Närvänenä O., Lehto S., Uusitıpa M. I. J., Ylä‐Herttuala S. Autoantibodies against oxidized low‐density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 204–9
   PubMed Web of Science ®Google Scholar
• Hulthe J., Wiklund O., Hurt‐Camejo E., Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 2001; 21: 269–74
   PubMedGoogle Scholar
• Weinbrenner T., Cladellas M., Covas M. I., Fito M., Tomas M., Senti M., et al. The SOLOS Study Investigators. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 2003; 168: 99–106
   PubMed Web of Science ®Google Scholar
• van de Vijver L. P., Steyger R., van Poppel G., Boer J. M., Kruijssen D. A., Seidell J. C., et al. Autoantibodies against MDA‐LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 1996; 122: 245–53
   PubMed Web of Science ®Google Scholar
• Monaco C., Crea F., Niccoli G., Summaria F., Cianflone D., Bordone R., et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. Eur Heart J 2001; 22: 1572–7
   PubMedGoogle Scholar
• Bergmark C., Wu R., de Faire U., Lefvert A. K., Swedenborg J. Patients with early‐onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441–5
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Pasternek R., Greenland P., Smith S., Fuster V. Assessment of cardivascular risk by use of multiple‐risk‐factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481–92
   PubMed Web of Science ®Google Scholar
• Shimada K., Mokuno H., Matsunaga E., Miyazaki T., Sumiyoshi K., Miyauchi K., et al. Circulating oxidized low‐density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004; 174: 343–7
   PubMedGoogle Scholar
• Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004; 11: 265–70
   PubMedGoogle Scholar
• Inoue N., Ohara Y., Fukai T., Harrson., D. G., Nishida K. Probucol improves endothelial‐dependent relaxation and decreases vascular superoxide production in cholesterol‐fed rabbits. Am J Med Sci 1998; 315: 242–7
   PubMed Web of Science ®Google Scholar
• Holvoet P., Mertens A., Verhamme P., Bogaerts K., Beyens G., Verhaeghe R., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844–8
   PubMed Web of Science ®Google Scholar
• Holvoet P., Jenny NS., Schreiner PJ., Tracy RP., Jacobs DR., for the Multi‐Ethnic Study of Atherosclerosis. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi‐Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2006
   Google Scholar
• Shoji T., Nishizawa Y., Fokumoto M., Shimamura K., Kimura J., Kanda H., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti‐oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171–7
   PubMed Web of Science ®Google Scholar
• Holvoet P., Macy E., Landeloos M., Jones D., Jenny N. S., Van de Werf F., et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52: 760–4
   PubMed Web of Science ®Google Scholar
• Lopes‐Virella M. F., Virella G., Orchard T. J., Koskinen S., Evans R. W., Becker D. J., et al. Antibodies to oxidized LDL and LDL‐containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999; 90: 165–72
   PubMed Web of Science ®Google Scholar
• Lehtimaki T., Lehtinen S., Solavaki T., Nikkila M., Jaakkola O., Jokela H., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23–7
   PubMed Web of Science ®Google Scholar
• Maggi E., Chiesa R., Melissano G., Castellano R., Astore D., Grossi A., et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892–9
   PubMed Web of Science ®Google Scholar
• Lopes‐Virella M. F., Binzafar N., Rackley S., Takei A., La Via M., Virella G. The uptake of LDL‐IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997; 135: 161–70
   PubMed Web of Science ®Google Scholar
• Ylä‐Herttuala S., Palinski W., Butler S. W., Picard S., Steinberg D., Witztum J. L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32–40
   PubMed Web of Science ®Google Scholar
• Schumacher M., Eber B., Tatzber F., Kaufmann P., Halwachs G., Fruhwald F. M., et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 1995; 18: 1087–91
   PubMedGoogle Scholar
• Cherubini A., Mecocci P., Senin U., Lowentha D. T., Barnert G., Chionne F. Autoantibodies against oxidized low‐density lipoproteins in older stroke patients. J Am Geriatr Soc 1997; 45: 125
   PubMedGoogle Scholar
• de Geest B., Collen D. Antibodies against oxidized LDL for non‐invasive diagnosis of atherosclerotic vascular disease. Eur Heart J 2001; 22: 1517–18
   PubMedGoogle Scholar
• Raitakari O. T., Pitkänen O‐P., Lehtimäki T., Lahdenperä S., Iida H., Ylä‐Herttuala S., et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97–102
   PubMed Web of Science ®Google Scholar
• Salonen J. T., Ylä‐Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883–7
   PubMed Web of Science ®Google Scholar
• Wu R., Nityanand S., Berglund L., Lithell H., Holm G., Lefvert A. K. Antibodies against cardiolipin and oxidatively modified LDL in 50‐year‐old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159–63
   PubMed Web of Science ®Google Scholar
• Craig W. Y., Poulin S. E., Neveux L. M., Palomaki G. E., Dostal‐Johnson D. A., Ledue T. B., et al. Anti‐oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipoprotein‐ and oxidation‐related analytes. J Autoimmun 1995; 8: 713–26
   PubMedGoogle Scholar